title: A newly synthesised molybdenum/ascorbic acid complex alleviates some effects of cardiomyopathy in streptozocin-induced diabetic rats.
abstract: BACKGROUND
  Exogenous insulin does not prevent cardiac failure in patients with type 1 diabetes mellitus and a cardioprotective insulin mimic is greatly needed. Certain transition metals are known to act as insulin mimics and may be cardio- protective. In this study, the ability of a newly synthesised molybdenum/ascorbic acid complex to strengthen cardiac function was investigated.
  
  
  METHODS
  Male CD rats were assigned to one of five groups: non-diabetic control, non-diabetic control treated with molybdenum/ascorbic acid complex, diabetic treated with sodium ascorbate, diabetic treated with molybdenum/ascorbic acid complex and untreated diabetics. Type 1 diabetes was induced by streptozocin injection. Once diabetes was confirmed, treatment was initiated by adding either the molybdenum/ascorbic acid complex or sodium ascorbate to the drinking water and continued for 6 weeks. Following the treatment period, the animals were terminated, and their hearts were excised and mounted in a working heart perfusion apparatus. Blood samples were taken for plasma glucose and plasma lipid level determination. Cardiac function was evaluated using 1 hour of low-flow ischaemic stress followed by 30 minutes of reperfusion.
  
  
  RESULTS
  Hearts from the animals treated with the molybdenum/ascorbic acid complex displayed the best aerobic performance of all the diabetic animals. Blood glucose levels and blood lipid levels were significantly lower in animals treated with the complex than in other diabetic animals. The group treated with the complex also had a lower drinking rate than the other diabetic groups. Furthermore, hearts from animals treated with the molybdenum/ascorbic acid complex showed a greater degree of recovery from low-flow ischaemia than any other group.
  
  
  CONCLUSIONS
  The molybdenum/ascorbic acid complex showed some significant insulin-mimic and cardioprotective effects. Further development of this complex could provide a drug useful for alleviating some of the cardiovascular problems associated with diabetes mellitus.
authors.affiliation: Department of Biology, Mount Allison University, Sackville, New Brunswick, Canada.
authors.forename: K
authors.initials: K
authors.lastname: MacDonald
authors.forename: J
authors.initials: J
authors.lastname: Bailey
authors.forename: C
authors.initials: C
authors.lastname: MacRory
authors.forename: C
authors.initials: C
authors.lastname: Friis
authors.forename: C M
authors.initials: CM
authors.lastname: Vogels
authors.forename: T
authors.initials: T
authors.lastname: Broderick
authors.forename: S A
authors.initials: SA
authors.lastname: Westcott
mesh_terms: D000818:Animals; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D009202:Cardiomyopathies / Q000517:prevention & control*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006321:Heart / Q000187:drug effects / Q000502:physiology; D007328:Insulin; D008055:Lipids / Q000097:blood; D008297:Male; D008982:Molybdenum / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000503:physiopathology; D051381:Rats; D011919:Rats, Inbred Strains; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D013311:Streptozocin; D008982:Molybdenum; D001205:Ascorbic Acid